According to the histological expression of ERα, PR, and HER2/ERRB2, breast cancer patients are divided into three therapeutic groups: ER-positive, HER2, and triple-negative breast cancer (TNBC) who receive hormone therapy, anti-HER2 target therapy, and chemotherapy, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.